Immunotoxin: A new tool for cancer therapy

Area of Science:

• Oncology
• Immunology
• Biotechnology

Background:

• Cancer remains a leading cause of death globally and in Iran.
• Immunotherapy has emerged as a key cancer treatment modality alongside chemotherapy and radiation.
• Immunotoxin therapy presents a promising approach within cancer treatment strategies.

Purpose of the Study:

• To explore the potential of immunotoxin therapy in cancer treatment.
• To discuss the composition and limitations of early-generation immunotoxins.
• To highlight current research trends in optimizing immunotoxins for cancer therapy.

Main Methods:

• Immunotoxins are constructed by conjugating a cytotoxic toxin to an antibody that targets cancer cell-specific proteins.
• Early immunotoxins utilized full-length toxins and whole monoclonal antibodies.
• The development of immunotoxins involves identifying target proteins on cancer cells.

Main Results:

• The first approved immunotoxin by the FDA was DAB389IL2.
• First-generation immunotoxins exhibited a lack of specificity, binding to normal cells.
• Ongoing research aims to improve immunotoxin efficacy and reduce immunogenicity.

Conclusions:

• Immunotoxin therapy offers a targeted approach to cancer treatment.
• Optimizing immunotoxin design is crucial for maximizing therapeutic benefits and patient safety.
• Future research will focus on developing more potent and less immunogenic immunotoxins.